D061605

4 trials

Sponsors

Okamatsu Hideharu, Yanagi Teruki, Ogasawara Sadahisa, Jun Oda

Conditions

Atrial fibrillation Atrial fibrillationSepsis or Septic shockextramammary Paget's disease extramammary Paget's diseasehepatocellular carcinoma

Phase 1

A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion

Active, not recruitingJPRN-jRCT2031210046

Ogasawara Sadahisahepatocellular carcinoma

Start: 2021-07-07Target: 15Updated: 2026-06-29

Phase 2

A phase II study of eribulin monotherapy for advanced extramammary Paget's disease

RecruitingJPRN-jRCT2011220022

Yanagi Terukiextramammary Paget's disease extramammary Paget's disease

Start: 2023-05-17Target: 18Updated: 2026-06-29

Single center, open-label Phase-IIa trial of tocilizumab in patients with sepsis or septic shock

RecruitingJPRN-jRCT2051230173

Jun OdaSepsis or Septic shock

Start: 2024-08-13Target: 60Updated: 2026-06-29

Unknown Phase

A Study on the Effect of Fluid Resuscitation on Renal Impairment Associated with Atrial Fibrillation Ablation Using Pulsed Field Ablation

Active, not recruitingJPRN-jRCT1070250077

Okamatsu HideharuAtrial fibrillation Atrial fibrillation

Start: 2025-09-16Target: 60Updated: 2026-06-29

Related Papers

Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.

Journal of Clinical Oncology2024-08-10

Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.

Journal of Clinical Oncology2024-01-20

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

BMJ Open2022-04-0111 citations

Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.

Journal of Clinical Oncology2022-01-191 citations